Meloxep

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxep

Quick Facts

Property Description
Active ingredient Meloxicam
Forms Oral Tablet, Capsule, Suspension, Injection Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use General relief of pain and inflammation
Origin Synthetic (Oxicam derivative)

What Type of Medicine is Meloxep?

Meloxep is a prescription medicinal product containing the active ingredient meloxicam, which is chemically derived and classified within the Nonsteroidal Anti-inflammatory Drug (NSAID) class. Meloxicam is a synthetic oxicam derivative of the enolic acid group. Clinically recognized for its targeted mechanism, it functions as a preferential cyclo-oxygenase-2 (COX-2) inhibitor. This classification is associated with the drug’s role in managing discomfort linked to inflammatory processes.

Forms, Composition, and Administration

Meloxep is available as a single-ingredient product in multiple pharmaceutical preparations to ensure flexibility in systemic administration. The medication is supplied as oral tablets, oral capsules, and a liquid oral suspension for the oral route. A sterile solution for intravenous injection is also produced for alternative administration. The composition consists of the active ingredient Meloxicam combined with pharmaceutical excipients for the solid forms, or a specialized aqueous vehicle when prepared as an injectable solution.

What is the General Purpose of Meloxep?

The general purpose of Meloxep is to provide symptomatic relief for inflammation and pain. It achieves this by exerting anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities. The medication’s action involves interfering with the synthesis of prostaglandins, which are chemical messengers responsible for triggering pain and swelling. This fundamental process ensures that the drug effectively modulates the body's physical response to tissue irritation, contributing to improved patient comfort.

What side effects are possible with Meloxep?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety information for Meloxep, strictly based on regulatory documents from government health authorities.


Serious Safety Warnings

Official regulatory labeling includes a Boxed Warning highlighting the risk of two serious, potentially fatal adverse reactions:

  • Cardiovascular Thrombotic Events: Meloxep may increase the risk of serious events like myocardial infarction (heart attack) and stroke. This risk may begin early in treatment and may increase with the duration of use.
  • Gastrointestinal Risk: The medicine can cause serious gastrointestinal adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning.

Common and Serious Adverse Reactions

Adverse reactions classified as Common in regulatory documents often involve the Gastrointestinal system (e.g., dyspepsia, abdominal pain, nausea) and the Nervous System (e.g., headache, dizziness).

Clinically significant adverse reactions (less common but serious) involve multiple System-Organ Classes, including the Hepatobiliary system (severe hepatic reactions, liver enzyme elevations), the Renal system (new-onset or worsening kidney dysfunction, hyperkalemia), and the Dermatological system (serious skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)).

Regulatory Limitations and Contraindications

Meloxep is Contraindicated (must not be used) in patients in the setting of coronary artery bypass graft (CABG) surgery and in those with a history of allergic-type reactions to aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Population-Specific Safety: Use is generally restricted or limited during late-term Pregnancy (from sim 30 weeks gestation) due to the risk of fetal harm, including the premature closure of the fetal ductus arteriosus and fetal renal dysfunction. Elderly patients and those with existing cardiovascular or gastrointestinal conditions require particular caution due to an increased risk of severe adverse events.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Meloxep (meloxicam) overdose documents specific manifestations and mandates immediate emergency action. This information is derived solely from authoritative government prescribing documents.

Documented Overdose Manifestations

Commonly documented signs following excessive intake include lethargy, drowsiness, nausea, vomiting, and epigastric pain. Regulators also note that gastrointestinal bleeding is a potential complication that may occur during overdose.

Severe and Life-Threatening Outcomes

Overdose may progress to high-risk systemic effects, which include acute renal failure, hepatic dysfunction, and severe central nervous system effects such as coma and convulsions. Life-threatening cardiovascular consequences like hypertension, cardiovascular collapse, and cardiac arrest are also explicitly documented by regulatory authorities.

When to Seek Immediate Medical Help

Given the potential for severe, life-threatening outcomes, regulatory authorities mandate that patients seek emergency medical attention immediately upon any suspected overdose. Emergency care is required for the presence of severe signs or complications, including anaphylactoid reactions.

Management and Antidote Status

The official guidance states that treatment is primarily symptomatic and supportive. There is no specific antidote known for meloxicam overdose. The administration of cholestyramine is officially described as a measure that can accelerate the elimination of meloxicam from the body.

Therapeutic Uses of Meloxep

Meloxep (meloxicam), which belongs to the category of nonsteroidal anti-inflammatory drugs (NSAIDs), is commonly used in situations involving certain distressing symptoms related to inflammatory or irritative states across conditions characterized by periods of heightened symptoms. The primary therapeutic domains for which Meloxep is applied are related to various forms of arthritis. The drug may assist with easing the signs and symptoms of osteoarthritis and rheumatoid arthritis in adults.

It is also relevant for easing the symptoms of juvenile rheumatoid arthritis in pediatric patients. The specific conditions for which Meloxep is used include adult osteoarthritis, adult rheumatoid arthritis, and juvenile rheumatoid arthritis (pauciarticular and polyarticular course). By addressing these symptom clusters, Meloxep helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

“This supportive management assists with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Relief for Joint Pain and Stiffness

Eligibility and Restrictions for Use

Official Population Eligibility for Meloxep

Meloxep (meloxicam) eligibility is strictly defined by regulatory authorities based on patient age, medical history, and physical status. Use is contraindicated in several specific populations.

Contraindications

Absolute prohibitions include patients with a known hypersensitivity to meloxicam or a history of allergic reactions, such as asthma or urticaria, following the administration of aspirin or other NSAIDs. Contraindications also apply to individuals with active or recurrent gastrointestinal (GI) ulceration or hemorrhage, a history of GI perforation related to prior NSAID use, and those with established severe heart failure or severely impaired liver/non-dialyzed renal function. The medicine is also prohibited for treating peri-operative pain in the setting of CABG surgery.

Age and Restricted Use

Meloxep is approved for adults and for pediatric patients 2 years of age and older for Juvenile Rheumatoid Arthritis. It is generally not recommended for children under 16 years in some regions. Older adults (ge 65 years) require careful monitoring. Patients on haemodialysis or those with certain cardiovascular conditions are limited to conditional use, such as a restricted maximum daily dosage or treatment only after careful consideration.

Pregnancy Status

Use is contraindicated during the third trimester of pregnancy and should be avoided from approximately 30 weeks gestation. Meloxep use is not recommended during lactation.

What should I know about interactions with other medicines?

Meloxep's interaction profile, as defined by official regulatory documents, details specific substance combinations and effects on drug exposure. Meloxep is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin at analgesic doses, is officially documented as avoided due to the heightened risk of serious gastrointestinal events.

Several pharmacodynamic and exposure-altering effects are officially noted. The risk of bleeding complications is increased with co-administration of oral anticoagulants such as Warfarin. Meloxep may officially diminish the therapeutic effect of Diuretics, ACE Inhibitors, and Angiotensin Receptor Blockers (ARBs). Furthermore, co-administration with Meloxep is associated with an officially documented increase in the plasma levels of both Lithium and Methotrexate.

Regarding drug metabolism, the primary clearance pathway relies on the CYP2C9 enzyme. Cholestyramine is documented to accelerate Meloxep's elimination, resulting in reduced systemic exposure. The risk of renal function deterioration when co-administered with ACE Inhibitors or ARBs is officially noted to be greater in the elderly and in volume-depleted patients. A high-fat meal officially results in a 22% higher peak concentration (Cmax) for the oral capsule formulation.

Mechanism of Action

Preferential Modulation of the Eicosanoid Pathway

Meloxep's core mechanism involves the preferential competitive inhibition of the enzyme Cyclo-oxygenase-2 ( COX-2). This action directly affects the eicosanoid pathway, leading to a targeted reduction in the synthesis of pro-inflammatory mediators, primarily prostaglandin E2 ( PGE2). This molecular modification alters the regulatory balance within the physiological cascade that initiates and sustains tissue responses.


Modulation of Peripheral Nociceptive Signaling

The decreased local concentration of PGE2 acts to desensitize peripheral nociceptors (sensory nerve endings), which are usually sensitized by these mediators. This physiological change contributes to decreasing the sensitization of nociceptors and reduces the influence of chemical mediators on the transmission of nociceptive signals. The mechanism also affects central systems, facilitating the adjustment of the hypothalamic temperature set-point.


Mechanism Constraint: Dose-Dependent Selectivity

The preferential mechanism is not absolute; Meloxep's inhibitory action extends to the constitutive COX-1 enzyme at higher exposures. This dose-dependent constraint helps define the functional boundaries of the COX-2 selectivity and influences the drug's overall effect profile by engaging mechanisms that regulate other crucial physiological processes.

Dosage and Administration Information

Meloxep is administered systemically via two routes: oral (using tablets, capsules, or suspension) and intravenous (IV) injection, utilizing specific formulations for each method. The standard oral dosing regimen for adults generally begins at 7.5 mg once daily, which can be adjusted to a maximum of 15 mg once daily based on individual response. The entire prescribed dose is administered as a single daily event. For certain formulations designed for intravenous use, the dosage is administered as a 30 mg bolus injection over 15 seconds, requiring the patient to be well hydrated prior to the procedure.

Oral Meloxep may be taken without regard to the timing of meals, though administration during a meal with water is also a recognized practice. Proper usage requires that any oral suspension be gently shaken before it is accurately measured for intake. The principle of treatment duration is to utilize the lowest effective dose for the shortest duration necessary to manage symptoms.

Specific instructions apply to certain populations. For instance, the oral dosage for pediatric patients with Juvenile Rheumatoid Arthritis (JRA) is based on body weight, starting at 0.125 mg per kilogram up to a maximum of 7.5 mg daily. Furthermore, for adult patients with end-stage renal disease who are undergoing hemodialysis, the maximum oral dose is restricted to 7.5 mg once daily. Procedures specify that different oral formulations are not interchangeable even if the total milligram strength appears identical.

Recent Clinical Evidence

Meloxep: Recent Clinical Evidence

Overview of Early Research

Initial studies investigated how the compound interacts with the body. These studies primarily focused on identifying the compound's effect on key processes relevant to pain and inflammation in trial participants, specifically those with chronic arthritis. The research design included comprehensive evaluations that investigated the timeframe of findings. Researchers also evaluated the scope of findings, which included observable changes related to joint swelling over the study period.


Randomized Controlled Trials (RCTs)

Several large, multicenter Phase 3 randomized controlled trials were conducted to rigorously evaluate the compound's effect on symptoms. For instance, a key trial involving approximately 5,000 participants reported a statistically significant change in pain scores during the defined observation period. The trials were designed to include adults meeting specific, predefined clinical criteria for the condition being studied. Further research also evaluated whether the use of the compound in combination with standard physical therapy led to different long-term mobility outcomes when compared to physical therapy alone.


Safety Profile and Comparative Findings

Extensive research has systematically evaluated the drug’s side effect profile across various patient groups in the trials. The collected data led to the research noting specific cautions for inclusion criteria, particularly concerning patients with pre-existing heart conditions. Details published from the trials indicate that the clinical protocol utilized a specific administration method. Additionally, other studies included comparisons of reported adverse events with different types of existing treatments to provide context on the compound's profile.

Key Studies & References

  1. Efficacy and Safety of Meloxep in Chronic Arthritis: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Meloxep (FAQ)


Q: Is Meloxep used to treat types of pain other than arthritis?

Meloxep is primarily approved for the long-term management of inflammatory conditions like osteoarthritis and rheumatoid arthritis. However, regulatory information confirms its general purpose is to provide symptomatic relief for inflammation and pain, indicating use for pain management beyond just arthritis.


Q: Why is Meloxep taken only once a day?

The official product information explains that Meloxep has a relatively long elimination half-life (approximately 20 hours). This pharmacological property is the key reason the medication is effective and designed to be administered once daily.


Q: What is Meloxep’s role in managing chronic versus acute pain?

Official indications for Meloxep typically focus on the long-term management of chronic conditions such as rheumatoid arthritis and osteoarthritis. The drug has also been studied and used to manage specific types of acute, short-term pain, such as the inflammation associated with acute gout flares.


Q: Are there recent studies about the long-term safety of Meloxep?

Regulatory documents include a Boxed Warning that emphasizes that the risk of serious side effects, such as cardiovascular events, may increase with the duration of use. This ongoing caution leads to continuous safety monitoring and research into the drug's long-term profile.


Q: Does Meloxep cause drowsiness or make you tired?

Official adverse event data indicates that Meloxep may cause effects on the nervous system, including drowsiness and general tiredness. These effects are reported by some patients during treatment.


Q: What is the recommended maximum duration of treatment with Meloxep?

Official regulatory guidance mandates that treatment should utilize the lowest effective dose for the shortest duration necessary to control symptoms. For chronic conditions, a specific, universal maximum time period for treatment is generally not stated in the official labeling.


Q: Why do official documents recommend taking the lowest effective dose of Meloxep?

Official product documents, including the Boxed Warning, recommend using the lowest effective dose to minimize the potential risk of severe adverse events. This guidance is specifically intended to limit the risk of serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding or ulcers).


Q: Can Meloxep be taken with low-dose aspirin?

Co-administration of Meloxep with analgesic doses of aspirin is officially avoided due to heightened risk of gastrointestinal events. Regulatory warnings state that co-administration increases the risk of serious bleeding. The decision regarding concurrent use of low-dose aspirin for cardiovascular prophylaxis is a clinical judgment.


Q: Does Meloxep affect blood pressure?

Official regulatory labeling notes that Meloxep may increase or worsen existing high blood pressure. This potential effect is a consideration because it could increase the risk of serious cardiovascular events. The potential effect means that blood pressure monitoring is a consideration during treatment, as described in official documents.


Q: Can Meloxep be taken at the same time as Tylenol (acetaminophen)?

Regulatory information does not typically list a direct interaction between Meloxep and acetaminophen (Tylenol). However, regulatory principles recommend that the use of any combination of pain relievers be discussed with a healthcare professional before use.


Q: How long does it typically take for Meloxep to start working for pain?

Meloxep is absorbed relatively slowly after an oral dose. While some initial pain relief may be noted within a few hours, the full anti-inflammatory effect and therapeutic benefit, especially for chronic conditions, are not instantaneous.


Q: How long does the effect of a single dose of Meloxep last?

According to official product data, the medication has an elimination half-life of approximately 20 hours. This long duration is the reason a single dose is designed to provide therapeutic effects that last throughout the day.


Q: What happens if a person forgets to take a dose of Meloxep?

Official patient information describes that a missed dose is generally taken as soon as it is remembered. If it is close to the time of the next scheduled dose, the guidance provided is to skip the missed dose and continue with the regular schedule to avoid taking a double dose.


Q: Is Meloxep considered a controlled substance?

Meloxep is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is only available by prescription. Official classification systems show that Meloxep is not classified as a controlled substance or narcotic.


Q: Are there restrictions on driving or operating machinery while taking Meloxep?

Official regulatory documents mention that Meloxep may cause side effects like drowsiness, dizziness, or light-headedness. Official documents caution that patients should know how the medication affects them before performing tasks that require full mental alertness, such as driving or operating heavy machinery.


Q: Can Meloxep cause unusual weight gain or swelling?

Official product labeling indicates that Meloxep can potentially cause fluid retention and edema (swelling) as an adverse effect. This swelling can sometimes lead to an unusual or sudden weight gain. These signs should be reported to a healthcare professional.


Q: Is it normal to not feel pain relief right away after starting Meloxep?

Yes, this is considered normal because Meloxep has a prolonged absorption phase. The medication begins working, but the maximum anti-inflammatory effect needed for significant relief, especially in chronic conditions, does not happen instantly.


Q: Can Meloxep be used for treating gout flares?

Meloxep is often described as a treatment option used for the acute pain and inflammation associated with gout flares. It is important to know that official indications for the standard Meloxep formulations vary across different regulatory agencies.


Q: What should be done about signs of an allergic reaction to Meloxep?

Official patient information emphasizes that if signs of a severe allergic reaction (such as hives, difficulty breathing, or swelling of the face or throat) occur, official guidance indicates that emergency medical help is sought immediately. This includes signs of severe skin reactions.


Q: Can Meloxep be used for migraine headaches?

While Meloxep (meloxicam) is sometimes available in a specialized, fixed-dose combination with another drug to treat acute migraine headaches, the single-ingredient Meloxep formulation is not typically indicated by regulatory bodies for migraine treatment.


Q: Does Meloxep affect the effectiveness of oral contraceptives?

Regulatory documents describe potential interactions with specific components of oral contraceptives, such as drospirenone, which may increase the risk of high potassium levels. Consultation with a healthcare provider is appropriate for patients using combined oral contraceptives to review potential interactions.


Q: What should I look out for regarding stomach bleeding while taking Meloxep?

Given the Boxed Warning for gastrointestinal risk, patients should be vigilant for signs of stomach bleeding. These signs, which include having black, bloody, or tarry stools or vomiting material that looks like coffee grounds, require immediate reporting to a doctor.


Q: Does Meloxep interact with antacids or acid-reducing medications?

While specific antacids may not have a documented interaction, regulatory information for some similar drugs suggests reduced absorption when taken concurrently with acid-reducing medications. Specific interactions with antacids or acid-reducing medications are typically confirmed with a healthcare provider.


Q: Does Meloxep affect vision or cause blurred vision?

Yes, official product data includes visual disturbances, such as blurred vision, among the possible side effects. Any new or worsening changes in vision are required to be reported to a healthcare provider promptly.

How should Meloxep be stored and disposed of?

Storage and Disposal Requirements for Meloxep

Official regulatory documents define specific conditions for storing and disposing of Meloxep (meloxicam) to maintain its stability.

Storage Conditions

Form Temperature Requirement Container and Environment
Oral Forms (Tablets/Capsules) Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) Must be stored in a tight container in a dry place to protect from moisture.
Injection Solution 25 C (77 F) Requires visual inspection for particulate matter or discoloration before use.

All forms of Meloxep must be kept out of the reach of children.

Handling and Disposal

If the Meloxep injection solution contains particulate matter or appears discolored upon inspection, the vial must be discarded. Unused or expired Meloxep must be disposed of strictly according to local regulations. Disposal should not involve flushing the product down the toilet or pouring it into a drain unless explicitly required by local guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloxep found in:

A-Z Index: